Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for ...
Cabometyx ® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or ...
The U.S. Food and Drug Administration has approved Exelixis Inc.’s (NASDAQ:EXEL) Cabometyx (cabozantinib) for two indications in adult and pediatric patients with previously treated, unresectable, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback